Efficacy and safety of choline alphoscerate (cereton) in patients with parkinson’s disease with cognitive impairments

An open 10-day study in which the therapeutic actions of Cereton were compared with those of piracetam was performed. Cereton was used in 40 patients (experimental group) at a dose of 1000 mg, while piracetam was used in 20 patients at a dose of 2000 mg; both agents were given as intravenous infusions in 200 ml of physiological saline on the background of antiparkinsonism agents. Patients’ status was evaluated using a complex of psychometric scales and neuropsychological tests, along with tools to assess the severity of the main symptoms of parkinsonism, side effects, and quality of life. Use of Cereton produced marked and moderate improvements in the state of cognitive functions more frequently than piracetam (40% and 25%, respectively), while the incidence of deterioration was lower (5% and 15%, p < 0.05). Cereton was very well tolerated by the patients: brief and short-term side effects were seen in only six patients (15%).

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Zh. M. Glozman, Quantitative Assessment of Neuropsychological Study Data [in Russian], Moscow (1999).

  2. 2.

    V. V. Zakharov, I. V. Damulin, and N. N. Yakhno, “Cognitive impairments in patients with Parkinson’s disease,” Zh. Nevrol. Psikhiat., 1, 13–19 (2005).

    Google Scholar 

  3. 3.

    O. S. Levin, “Mental disorders in patients with Parkinson’s disease and their correction,” in: Extrapyramidal Disorders. Handbook for Diagnosis and Treatment [in Russian], Medpress-Inform, Moscow (2002), pp. 125–151.

  4. 4.

    O. S. Levin and N. V. Fedorova, Parkinson’s Disease [in Russian], Moscow (2006).

  5. 5.

    O. S. Levin, L. A. Batukaeva, and I. G. Smolentseva, “Diagnosis and treatment of dementia in Parkinson’s disease,” Zh. Nevrol. Psikhiat., 6, 85–91 (2008).

    Google Scholar 

  6. 6.

    I. V. Litvinenko, Parkinson’s Disease [in Russian], Moscow (2006).

  7. 7.

    A. R. Luriya, Higher Cortical Functions in Humans and theirImpairments in Local Brain Lesions [in Russian], Moscow State University, Moscow (1969).

    Google Scholar 

  8. 8.

    A. Yu. Panasyuk, An Adapted Variant of the Wechsler Test [in Russian], Research Institute Psychiatry, Moscow (1983).

    Google Scholar 

  9. 9.

    D. Aarsland, K. Andersen, J. P. Larsen, et al., “Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study,” Arch. Neurol., 60, 387–392 (2003).

    Article  PubMed  Google Scholar 

  10. 10.

    F. Amenta, L. Parnetti,V. Gallasi, et al., “Treatment of cognitive dysfunction associated with Alzheimer disease with cholinergic precursors,” Mech. Aging Dev., 122, 2025 (2001).

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    R. Brooks, R. Rabin, and F. de Charro, The Measurement and Valuation of Health Status Using EQ-5D, Kluwer Academic Publishers (2003).

  12. 12.

    J. L. Cummings, Cholinesterase inhibitors for treatment of dementia associated with Parkinson’s disease,” J. Neurol. Neurosurg. Psychiat., 76, 903–904 (2005).

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    M. Emre, D. Aarsland, A. Albanese, et al., “Rivastigmine for dementia associated with Parkinson’s disease,” New Engl. J. Med., 351, 2509–2518 (2004).

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    M. Emre, D. Aarsland, R. Brown, et al., “Clinical diagnostic criteria for dementia associated with Parkinson disease,” Mov. Dis., 22, 1689–1707 (2007).

    Article  Google Scholar 

  15. 15.

    S. Fahn and R. L. Elton, “Unified Rating Scale for Parkinson’s Disease,” in: Recent developments in Parkinson’s Disease, S. Fahn and C. D. Marsden (eds.), Macmillan, Florham Park, New York, pp. 153–163.

  16. 16.

    M. F. Folstein, S. E. Folstein, and P. R. McHugh, Mini-mental status,” J. Psychiat. Res., 12, 189–196 (1975).

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    W. Gibb and A. Lees, “The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease,” J. Neurol. Neurosurg. Psychiat., 51, 745–752 (1988).

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    M. A. Hely, J. G. Morris, W. G. Reid, et al., “Sydney multicenter study of Parkinson’s disease,” Mov. Dis., 23, 837–844 (2008).

    Article  Google Scholar 

  19. 19.

    M. Hoehn and M. D. Jahr, “Parkinsonism: onset, progression and mortality,” Neurology, 17, No. 5, 427–442 (1967).

    CAS  PubMed  Google Scholar 

  20. 20.

    H. Lehfeld and H. Erzigkeit, “The SKT-A Short Cognitive Performance Test for Assessing Deficits of Memory and Attention,” Int. Psychogeriat., 9, 115–121 (1997).

    Article  Google Scholar 

  21. 21.

    P. J. Manos and R. Wu, “The ten point clock test,” Int. J. Psych. Med., 24, 229–244 (1994).

    CAS  Article  Google Scholar 

  22. 22.

    L. Parnetti, F. Mignini, D. Tomasssoni, et al., “Cholinergic precursors in the treatment of cognitive impairment of vascular origin,” J. Neurol. Sci., 257, 264–269 (2007).

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    E. Perry, M. Walker, J. Grace, and R. Perry, “Acetylcholine in mind: a neurotransmitter correlate of consciousness?” Trends Neurosci., 22, 273–280 (1999).

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    S. E. Starkstein and M. Merello, Psychiatric and Cognitive Disorders in Parkinson’s Disease, Cambridge University Press, Cambridge (2002).

    Book  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to O. S. Levin.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 109, No. 11, pp. 42–46, November, 2009.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Levin, O.S., Batukaeva, L.A., Anikina, M.A. et al. Efficacy and safety of choline alphoscerate (cereton) in patients with parkinson’s disease with cognitive impairments. Neurosci Behav Physi 41, 47–51 (2011). https://doi.org/10.1007/s11055-010-9377-2

Download citation

Key Words

  • Parkinson’s disease
  • cognitive impairments
  • correction
  • Cereton (choline alphoscerate)